Poseida Therapeutics Hires General Counsel and CCO
“Poseida Therapeutics, which launched its IPO on Nasdaq earlier this month, has hired Harry Leonhardt as general counsel and chief compliance officer (CCO),” reports Ben Maiden in Corporate Secretary’s Appointments.
“Leonhardt was most recently senior vice president, general counsel, CCO, corporate secretary and a member of the executive committee at Halozyme Therapeutics. Before working at Halozyme, he was senior vice president for legal and compliance, corporate secretary and a member of the executive committee at Amylin Pharmaceuticals, which was acquired by Bristol Myers Squibb in 2012.”
“Earlier in his career, Leonhardt served as general counsel for a number of San Diego, California-based biotech companies, and as chief litigation counsel and later as general counsel for the European region at Allergan Pharmaceuticals. Before that he was an intellectual property litigator in Los Angeles.”
